Proov, known for its PdG-test and full cycle tracking kit is launching another product: The Proov Check Early Pregnancy Test. The new test allows women to use the tests up to five days before their next expected period to detect hCG (human Chorionic Gonadotropin) in urine, which is only present when pregnant. Results can be expected within 5 minutes of taking the…
Mirvie‘s proprietary RNA platform combines revolutionary analysis of tens of thousands of RNA messages from the baby, the placenta and the mom, with machine learning. The platform opens a new window into pregnancy health for expecting parents to act and their doctors to intervene before unexpected complications become a crisis. It can predict preeclampsia and preterm birth months before they happen by…
Natural Cycles, the FDA-cleared birth control app is introducing ‘Recovery Mode’ to support users who experience pregnancy loss before 20 weeks. The new feature was developed to help women who used its NC° Plan Pregnancy to conceive and whose pregnancy results in miscarriage as they recover physically and emotionally. About one in four pregnancies end in a miscarriage – a rate consistent with…
Last year Los-Angeles based maternal health company Ruth Health went through Y-Combinator and UnitedHealthcare Accelerator Powered by Techstars. Today, as the company is preparing for further growth, they are announcing a $2.4M seed round led by Giant Ventures. Other participants in the round include Citylight VC, Cleo Capital Scout Fund, Crista Galli Ventures, Duro VC, Emmeline Ventures, Gaingels, Global Founders Capital, Pentas…
Australia-based Baymatob has raised AS4.215 ($3M) to continue clinical trials for its AI-guided labor monitoring device, Oli, that can predict postpartum hemorrhage, a leading cause of maternal death. The round was led by Australian Unity’s future of Healthcare Fund and supported by other institutional and high net worth investors. Bamyatob was founded in 2013 by Dr. Sarah McDonald after her own traumatic…
Biotech firm Renegade.bio and Metabolomic Diagnostics are teaming up to develop a novel pre-eclampsia risk screening test, with plans to launch in the U.S. in late 2022. The test will be jointly developed specifically for the U.S. population, improving upon available assessments by creating a personalized risk profile for individuals. It measures a panel of biomarkers in blood that serves as early…
A new study on the effect of the COVID-19 virus in pregnancy has been published in the American Journal of Obstetrics and Gynecology. Analyzing data from 42754 pregnant women infected with the COVID-19 virus during pregnancy, the results of this systematic review and meta-analysis suggest a “strong connection between COVID infection and preterm delivery as well as an increased risk of cesarian…
Mitera, a Mountain View-based company that provides telehealth services to address preganancy-related risks, has launched two new services today. 23Pears, an at-home expanded carrier screening test (ECS) that screens for 421 genes, and Peaches&Me, the the first at-home non-invasive prenatal test (NIPT), are now available throughout the U.S. Expanded carrier screening (which 23Pears offers) allows parents-to-be to examine their DNA and find…
